Dr. Xing is the Francis West Lewis Chair and director of the Center for Computational and Genomic Medicine at CHOP, and professor of Pathology and Laboratory Medicine at the University of Pennsylvania. His research focuses on computational biology and genomics of RNA processing and regulation.
Dr. Gonzalez-Alegre's long-range research goal is to advance the application of precision medicine in the neurology clinic. His research focus revolves around genetic disorders that affect the brain, spanning from the diagnosis of novel genetic disease in the clinic to the identification of novel molecular targets using disease models and the design of early-phase human clinical trials.
Dr. Hunger's focuses his research on molecular and genomic approaches to identify and clinically evaluate targeted cancer treatments for children with relapsed or high-risk acute lymphoblastic leukemia (ALL) such as Philadelphia chromosome-like (Ph-Like) ALL. The long-term goal of Dr. Hunger’s research is to develop better therapies, improve cure rates, and minimize treatment toxicities for children with ALL.
Dr. Furth's research focuses on defining risk factors for kidney disease progression in children; characterizing the effect of kidney function decline on neurodevelopment, cognitive abilities and behavior; identifying the prevalence and evolution of cardiovascular disease risk factors, and examining the effects of declining glomerular filtration rate on children’s growth.
Dr. Goldberg's research program focuses on investigating cerebral cortical circuit function and dysfunction in neurodevelopmental disorders. Using a variety of research techniques, Dr. Goldberg has a specific research interest in the workings of neuron subtype called GABAergic inhibitory interneuron and the role of interneuron dysfunction in disease.
Dr. Maris investigates the molecular and genetic mechanisms contributing to the development and progression of neuroblastoma, a common childhood cancer. He also aims to develop new molecular diagnostic tests and less toxic, targeted therapies to treat relapsed or refractory neuroblastoma, including a major effort in immunotherapy discovery and development.
Dr. Kelsen’sresearch focus is on the genetic, immunologic, and microbiomic causes of very early onset inflammatory bowel disease. Through a multidisciplinary team approach, Dr. Kelsen and her colleagues perform genetic sequencing to identify causative genetic variants in children with VEO-IBD, study the function of these variants, and use this information to improve the clinical outcomes for these children.
Dr. Oliver investigates the mechanisms governing T cell activation and protective immunity. Her goal is to define mechanisms that, when dysregulated, result in autoimmunity or allergic disorders like asthma.
Dr. Tasian and his research team use an epidemiologic framework, including randomized trials and multi-institutional observational studies, to examine the etiology of kidney stone disease and the comparative effectiveness of surgical interventions. He also employs machine learning of complex data to improve diagnosis, risk stratification, and prediction of treatment response for children and adults with benign urologic disease.